{
  "paper": {
    "title": "SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade",
    "doi": "10.1038/s41586-025-09006-8",
    "publication_year": 2025,
    "domain": "oncology-immunology",
    "study_type": "preclinical+retrospective"
  },
  "core_question": "Does intratumoral delivery of an mRNA vaccine sensitize tumors to immune checkpoint blockade by creating an interferon-rich inflammatory state?",
  "datasets_or_cohorts": [
    {
      "id": "mouse-efficacy-combo",
      "label": "Mouse Combination Efficacy Cohort",
      "sample_size_or_observations": "78 mice",
      "description": "Tumor-bearing mice receiving the combined treatment of intratumoral mRNA vaccine and anti-PD-L1 checkpoint blockade to assess efficacy."
    },
    {
      "id": "mouse-control-groups",
      "label": "Mouse Control Cohorts",
      "sample_size_or_observations": "84 mice",
      "description": "Tumor-bearing mice used for matched controls, including vaccine-only, ICI-only, and vehicle groups."
    },
    {
      "id": "human-retrospective-ici",
      "label": "Human Retrospective Metastatic Cohort",
      "sample_size_or_observations": "130 patients total",
      "description": "Metastatic cancer patients receiving ICI treatment, divided into vaccinated (43 patients) and unvaccinated (87 patients) subgroups based on prior SARS-CoV-2 mRNA vaccination status."
    }
  ],
  "major_limitations": [
    "The human analysis is retrospective and non-randomized; residual confounding is likely.",
    "Vaccination timing relative to ICI initiation varied across patients.",
    "Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.",
    "Mouse model effects may not map one-to-one to all human tumors."
  ]
}